AKT1 and breast carcinoma: AKT2 and AKT3 amplifications are observed more frequently (0.85%, 0.70%), and AKT1 amplification was less (0.48%) among AKT isoforms in the GENIE breast cancer cohort, as seen in Supplemental Figure S1).